Your browser doesn't support javascript.
loading
Real-World Utilization, Barriers, and Factors Associated With the Targeted Treatment of Metastatic Colorectal Cancer Patients in China: A Multi-Center, Hospital-Based Survey Study.
Liu, Yin; Zhang, Xi; Xu, Hui-Fang; Shi, Ji-Hai; Zhao, Yu-Qian; Du, Ling-Bin; Liu, Yun-Yong; Wang, Wen-Jun; Cao, He-Lu; Ma, Li; Huang, Juan-Xiu; Cao, Ji; Li, Li; Fan, Yan-Ping; Gu, Xiao-Fen; Feng, Chang-Yan; Zhu, Qian; Wang, Xiao-Hui; Du, Jing-Chang; Zhang, Jian-Gong; Zhang, Shao-Kai; Qiao, You-Lin.
Afiliación
  • Liu Y; Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
  • Zhang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.
  • Xu HF; Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
  • Shi JH; The Clinical Epidemiology of Research Center, Department of Dermatological, The First Affiliated Hospital of Baotou Medical College, Baotou, China.
  • Zhao YQ; Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • Du LB; Department of Cancer Prevention, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
  • Liu YY; Liaoning Office for Cancer Control and Research, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Wang WJ; School of Nursing, Jining Medical University, Jining, China.
  • Cao HL; Department of Preventive Health, Xinxiang Central Hospital, Xinxiang, China.
  • Ma L; Public Health School, Dalian Medical University, Dalian, China.
  • Huang JX; Department of Gastroenterology, Wuzhou Red Cross Hospital, Wuzhou, China.
  • Cao J; Department of Cancer Prevention and Control Office, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Li L; Department of Clinical Research, The First Affiliated Hospital, Jinan University, Guangzhou, China.
  • Fan YP; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Gu XF; Department of Student Affairs, Affiliated Tumor Hospital, Xinjiang Medical University, Ürümqi, Xinjiang, China.
  • Feng CY; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Zhu Q; School of Public Health and Management, Chongqing Medical University, Chongqing, China.
  • Wang XH; Department of Public Health, Gansu Provincial Cancer Hospital, Lanzhou, China.
  • Du JC; School of Public Health, Chengdu Medical College, Chengdu, China.
  • Zhang JG; Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
  • Zhang SK; Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
  • Qiao YL; Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
Int J Public Health ; 68: 1606091, 2023.
Article en En | MEDLINE | ID: mdl-37465051
Objectives: To explore the utilization, barriers, and factors associated with the targeted treatment of Chinese metastatic colorectal cancer (mCRC) patients. Methods: A total of 1,688 mCRC patients from 19 hospitals in 14 cities were enrolled from March 2020 to March 2021 using stratified, multistage cluster sampling. The use of targeted therapy and any barriers patients experienced were collected. Logistic regression analyses were conducted to identify the factors associated with initiating targeted treatment. Results: About 51.6% of the patients initiated targeted therapy, of whom 44.5%, 20.2%, and 35.2% started first-, second-, and third-line treatment, respectively. The most reported barriers were high medical costs and a lack of belief in the efficacy of targeted therapy. Patients treated in the general hospital, diagnosed at an older age, less educated, and who had a lower family income, no medical insurance, poor health-related quality of life, metastasis outside the liver/lung or systemic metastasis, a shorter duration of mCRC were less likely to initiate targeted therapy. Conclusion: Reduced medical costs and interventional education to improve public awareness could facilitate the use of targeted treatment for mCRC.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias del Colon Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Public Health Asunto de la revista: SAUDE PUBLICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Neoplasias del Colon Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Public Health Asunto de la revista: SAUDE PUBLICA Año: 2023 Tipo del documento: Article